CSL Ltd
ASX:CSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Riot Blockchain Inc
NASDAQ:RIOT
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (32), the stock would be worth AU$349.48 (169% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | AU$130 |
0%
|
| 3-Year Average | 32 | AU$349.48 |
+169%
|
| 5-Year Average | 32.2 | AU$351.65 |
+171%
|
| Industry Average | 15.7 | AU$171.87 |
+32%
|
| Country Average | 13.2 | AU$144.43 |
+11%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 11.9 | 30.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 18.5 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 18.6 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 16.2 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 30.1 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 16 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 119.3 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD | 77.2 | 128.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
CSL Ltd
Glance View
In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.
